ScienceMed®

Could Less Be More? Accounting for Fractional-Dose Regimens and Different Number of Vaccine Doses When Measuring the Impact of the RTS,S/AS01E Malaria Vaccine

Infectologia

Ensaio clínico randomizadoNível 2 · Nova evidênciaThe Journal of infectious diseases16 ago 20244 citações

Salvar

Resumo original em inglês

O que aconteceu

The RTS,S/AS01E (RTS,S) malaria vaccine is recommended for children in malaria endemic areas. This phase 2b trial evaluates RTS,S fractional- and full-dose regimens in Ghana and Kenya.

In total, 1500 children aged 5-17 months were randomized (1:1:1:1:1) to receive RTS,S or rabies control vaccine. RTS,S groups received 2 full RTS,S doses at months 0 and 1 and either full (groups R012-20, R012-14-26) or fractional doses (one-fifth; groups Fx012-14-26, Fx017-20-32).

NCT03276962 (ClinicalTrials.gov).

O que encontraram

At month 32 post-dose 1, vaccine efficacy against clinical malaria (all episodes) ranged from 38% (R012-20; 95% confidence interval [CI]: 24%-49%) to 53% (R012-14-26; 95% CI: 42%-62%). Vaccine impact (cumulative number of cases averted/1000 children vaccinated) was 1344 (R012-20), 2450 (R012-14-26), 2273 (Fx012-14-26), and 2112 (Fx017-20-32). To account for differences in vaccine volume (fractional vs full dose; post hoc analysis), we estimated cases averted/1000 RTS,S full-dose equivalents: 336 (R012-20), 490 (R012-14-26), 874 (Fx012-14-26), and 880 (Fx017-20-32).

Por que isso importa

Vaccine efficacy was similar across RTS,S groups. Vaccine impact accounting for full-dose equivalence suggests that using fractional-dose regimens could be a viable dose-sparing strategy. If maintained through trial end, these observations underscore the means to reduce cost per regimen thus maximizing impact and optimizing supply.

Resumo publicado sob licença CC BY. A tradução para o português ainda não chegou a este estudo.

O estudo original

Could Less Be More? Accounting for Fractional-Dose Regimens and Different Number of Vaccine Doses When Measuring the Impact of the RTS,S/AS01E Malaria Vaccine

Nelli Westercamp, Lawrence Osei-Tutu, Lode Schuerman, Simon K Kariuki, Anne Bollaerts, Cynthia K Lee, Aaron M Samuels, Christian Ockenhouse, Dennis K Bii, Samuel Adjei et al.

Descritores MeSH

  • Vaccine Efficacy
  • Malaria, Falciparum
  • Malaria Vaccines
  • Humans
  • Immunization Schedule
  • Infant
  • Kenya
  • Malaria
  • Male
  • Plasmodium falciparum

Veja também

Estudos relacionados